Mayo Clinic Validation of the D'Amico Risk Group Classification for Predicting Survival Following Radical Prostatectomy

Journal of Urology

Volumn 179, Issue 4, 2008, Pages 1354-1361

  Boorjian, Stephen A ^a   Karnes, R Jeffrey ^a   Rangel, Laureano J ^a   Bergstralh, Eric J ^a   Blute, Michael L ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

prostate; prostate specific antigen; prostatectomy; prostatic neoplasms; risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; GLEASON SCORE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; VALIDATION STUDY;

AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 40849083344     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.11.061     Document Type: Article

References (19)

1. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
2. Kattan M.W., Eastham J.A., Stapleton A.M.F., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766
3. Blute M.L., Bergstralh E.J., Iocca A., Scherer B., and Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165 (2001) 119
4. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco Jr. F.J., Dotan Z.A., DiBlasio C.J., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005
5. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910
6. Ward J.F., Blute M.L., Slezak J., Bergstralh E.J., and Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170 (2003) 1872
7. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
8. Albertson P.C., Hanley J.A., Gleason D.F., and Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280 (1998) 975
9. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., and Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2002) 4567
10. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163
11. Mitchell J.A., Cooperberg M.R., Elkin E.P., Lubeck D.P., Mehta S.S., Kane C.J., et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 173 (2005) 1126
12. Thompson R.H., Blute M.L., Slezak J.M., Bergstralh E.J., and Leibovich B.C. Is the GPSM scoring algorithm for prostate cancer patients valid in the contemporary era?. J Urol 178 (2007) 459
13. Cooperberg M.R., Lubeck D.P., Mehta S.S., and Carroll P.R. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170 (2003) S21
14. Kane C.J., Presti J.C., Amling C.L., Aronson W.J., Terris M.K., and Freedland S.J. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 177 (2007) 113
15. Meng M.V., Elkin E.P., Latini D.M., Duchane J., and Carroll P.R. Treatment of patients with high risk localized prostate cancer: results form Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol 173 (2005) 1557
16. Messing E.M., Manola J., Yao J., Kiernan M., Crawford D., Wilding G., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472
17. Smith M.R., O'Malley A.J., and Keating N.L. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448
18. Manoharan M., Bird V.G., Kim S.S., Civantos F., and Soloway M.S. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8. BJU Int 92 (2003) 539
19. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005) 751